Evaluation of Canadian pharmaceutical pricing

Charles River Associates Yellow Pill Production Line

CRA’s Andrew Tepperman provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by pharmaceutical companies in Canada. CRA’s team addressed the application of published guidelines by the PMPRB, and the relationship between certain tests described in those guidelines and other means of evaluation whether drug prices are excessive.

Meet our team